Milestone Pharmaceuticals (MIST) Other financing activities (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Other financing activities came in at $8.3 million in Q1 2026, up 5822.14% YoY from $140000.0 in Q1 2025, and up 2798.95% on a QoQ basis from $286000.0 in Q4 2025.
Milestone Pharmaceuticals (MIST) Other financing activities (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 9 years of Other financing activities data on file, last reported at $8.3 million in Q1 2026.
- Quarterly Other financing activities rose 5822.14% year-over-year to $8.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (up 11209.21% YoY) and the FY2025 annual result came in at $444000.0, up 737.74% from the prior year.
- Other financing activities grew to $8.3 million in Q1 2026, from $286000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $8.3 million in Q1 2026 to a low of -$179000.0 in Q4 2022.
- A 5-year average of $658500.0 and a median of $83000.0 in 2022 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2024 — Other financing activities sank 563.16% — and 2026, when it surged 5822.14%.
- Tracing MIST's Other financing activities over 5 years: stood at -$179000.0 in 2022, then surged by 236.87% to $245000.0 in 2023, then tumbled by 90.2% to $24000.0 in 2024, then surged by 1091.67% to $286000.0 in 2025, then surged by 2798.95% to $8.3 million in 2026.
- The last three Other financing activities figures came in at $8.3 million (Q1 2026), $286000.0 (Q4 2025), and $18000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.91 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.87 Bn | 59.68 Bn | 1.37 Bn |
| 4 | Moderna | 58.18 Bn | 53.04 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.96 Bn | 36.87 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.23 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.79 Bn | 9.40 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.37 Bn | 26.53 Bn | - |
| 10 | Milestone Pharmaceuticals | 43.32 Mn | -128.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.12 Mn |
| Jun 30, 2026 | 9.12 Mn |
| Mar 31, 2026 | 8.29 Mn |
| Mar 31, 2026 | 8.29 Mn |
| Dec 31, 2025 | 286,000.00 |
| Dec 31, 2025 | 286,000.00 |
| Sep 30, 2025 | 18,000.00 |
| Sep 30, 2025 | 18,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Dec 31, 2024 | 24,000.00 |
| Dec 31, 2024 | 24,000.00 |
| Jun 30, 2024 | -88,000.00 |
| Jun 30, 2024 | -88,000.00 |
| Mar 31, 2024 | 117,000.00 |
| Mar 31, 2024 | 117,000.00 |
| Sep 30, 2023 | 245,000.00 |
| Sep 30, 2023 | 245,000.00 |
| Jun 30, 2023 | 19,000.00 |
| Jun 30, 2023 | 19,000.00 |